Will engineered T cells expressing CD20 scFv eradicate melanoma?

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 638-640

  Somasundaram, Rajasekharan ^a   Villanueva, Jessie ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; MELANOMA ANTIGEN; MELANOTRANSFERRIN; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFERRIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER INHIBITION; GENETIC ENGINEERING; HUMAN; LYMPHOMA; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE; T LYMPHOCYTE;

EID: 79953314278     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.46     Document Type: Note

References (20)

1. Miller, AJ and Mihm, MC Jr (2006). Melanoma. N Engl J Med 2006, 355:51-65.
2. Flaherty, KT, Puzanov, I, Kim, KB, Ribas, A, McArthur, GA, Sosman, JA et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
3. Flaherty, KT, Hodi, FS and Bastian, BC (2010). Mutation-driven drug development in melanoma. Curr Opin Oncol 22: 178-183.
4. Villanueva, J, Vultur, A, Lee, JT, Somasundaram, R, Fukunaga-Kalabis, M, Cipolla, AK et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
5. Roesch, A, Fukunaga-Kalabis, M, Schmidt, EC, Zabierowski, SE, Brafford, PA, Vultur, A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
6. Nazarian, R, Shi, H, Wang, Q, Kong, X, Koya, RC, Lee, H et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
7. Johannessen, CM, Boehm, JS, Kim, SY, Thomas, SR, Wardwell, L, Johnson, LA et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
8. Tedder, TF and Engel, P (1994). CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450-454. (Pubitemid 24272191)
9. Schmidt, P, Kopecky, C, Hombach, A, Zigrino, P, Mauch, C and Abken, H (2011). Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108: 2474-2479.
10. Schatton, T, Murphy, GF, Frank, NY, Yamaura, K, Waaga-Gasser, AM, Gasser, M et al. (2008). Identifi- cation of cells initiating human melanomas. Nature 451: 345-349.
11. Fang, D, Nguyen, TK, Leishear, K, Finko, R, Kulp, AN, Hotz, S et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
12. Boiko, AD, Razorenova, OV, van de Rijn, M, Swetter, SM, Johnson, DL, Ly, DP et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133-137.
13. Dick, JE (2009). Looking ahead in cancer stem cell research. Nat Biotechnol 27: 44-46.
14. Chattopadhyay, P, Kaveri, SV, Byars, N, Starkey, J, Ferrone, S and Raychaudhuri, S (1991). Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1. Cancer Res 51: 6045-6051.
15. Quintana, E, Shackleton, M, Sabel, MS, Fullen, DR, Johnson, TM and Morrison, SJ (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
16. Quintana, E, Shackleton, M, Foster, HR, Fullen, DR, Sabel, MS, Johnson, TM et al. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
17. Lamers, CH, Sleijfer, S, Vulto, AG, Kruit, WH, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-22.
18. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis SA et al. (2006). A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115. (Pubitemid 44703776)
19. Jazirehi, AR and Bonavida, B (2005). Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24: 2121-2143. (Pubitemid 40516580)
20. Shackleton, M, Quintana, E, Fearon, ER and Morrison, SJ (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.